<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01366339</url>
  </required_header>
  <id_info>
    <org_study_id>MNTX 1201</org_study_id>
    <nct_id>NCT01366339</nct_id>
  </id_info>
  <brief_title>Tolerance and Pharmacokinetics Study of MNTX Tablets</brief_title>
  <official_title>A Replicate Design, Double-Blind, Randomized, Placebo-Controlled Tolerance and Pharmacokinetics Study of N-Methylnaltrexone Tablets in Normal, Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, phase I study in normal healthy
      volunteers. Study treatment includes single doses of MNTX and placebo. In addition, half of
      each active treatment group is further randomized to a second, replicate dose of MNTX, and
      the placebo group receives an additional placebo dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of oral doses of MNTX</measure>
    <time_frame>7 days</time_frame>
    <description>To determine PK, dose proportionality, and urinary excretion of single, oral doses of MNTX in normal healthy volunteers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Time of Maximum Concentration (Tmax) of oral doses of MNTX</measure>
    <time_frame>7 days</time_frame>
    <description>To determine PK, dose proportionality, and urinary excretion of single, oral doses of MNTX in normal healthy volunteers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration versus Time Curve (AUC) of oral doses of MNTX</measure>
    <time_frame>7 days</time_frame>
    <description>To determine PK, dose proportionality, and urinary excretion of single, oral doses of MNTX in normal healthy volunteers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of oral doses of MNTX</measure>
    <time_frame>7 days</time_frame>
    <description>To determine PK, dose proportionality, and urinary excretion of single, oral doses of MNTX in normal healthy volunteers</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Normal Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral methylnaltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral methylnaltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral methylnaltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral methylnaltrexone</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral placebo</intervention_name>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Weight between 55 and 85 kg

          2. In good health with no evidence of a clinically significant chronic medical condition

          3. Non-Smokers.

        Exclusion Criteria:

          1. History of asthma, allergic skin rash, significant allergy or other immunologic
             disorder

          2. Known or suspected hypersensitivity to opioids or opioid antagonists

          3. History or suspicion of alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tage Ramakrishna, MD</last_name>
    <role>Study Director</role>
    <affiliation>Progenics Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Progenics Pharmaceuticals, Inc.</name>
      <address>
        <city>Tarrytown</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2011</study_first_posted>
  <last_update_submitted>July 17, 2011</last_update_submitted>
  <last_update_submitted_qc>July 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tage Ramakrishna, MD</name_title>
    <organization>Progenics Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylnaltrexone</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

